Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout
Data From Second Phase III, US Filing Expected In 2024
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.